BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations
BD (NYSE: BDX) and Babson Diagnostics announced an expansion of their fingertip blood collection and testing technologies for U.S. health systems and provider networks. The innovation combines BD's MiniDraw™ Capillary Blood Collection System with Babson's BetterWay technologies, requiring only six drops of blood from a finger prick. The system can be operated by any trained healthcare worker without phlebotomy experience.
This development aims to improve access to blood testing in underserved locations and reduce barriers like needle fear and logistical challenges. The partnership, which began in 2016, has already implemented BetterWay blood testing in retail settings since May 2024 and is now expanding to ambulatory care sites across the United States.
BD (NYSE: BDX) e Babson Diagnostics hanno annunciato un'espansione delle loro tecnologie di raccolta e analisi del sangue a livello di punta per i sistemi sanitari e le reti di fornitori negli Stati Uniti. L'innovazione combina il MiniDraw™ Capillary Blood Collection System di BD con le tecnologie BetterWay di Babson, richiedendo solo sei gocce di sangue da una puntura del dito. Il sistema può essere utilizzato da qualsiasi operatore sanitario formatore, senza necessità di esperienza in flebotomia.
Questo sviluppo mira a migliorare l'accesso ai test del sangue in luoghi svantaggiati e a ridurre le barriere come la paura degli aghi e le sfide logistiche. La partnership, avviata nel 2016, ha già implementato il test del sangue BetterWay in contesti retail da maggio 2024 e ora si sta espandendo nei siti di assistenza ambulatoriale negli Stati Uniti.
BD (NYSE: BDX) y Babson Diagnostics anunciaron una expansión de sus tecnologías de recolección y análisis de sangre en el dedo para los sistemas de salud y redes de proveedores en los Estados Unidos. La innovación combina el MiniDraw™ Capillary Blood Collection System de BD con las tecnologías BetterWay de Babson, requiriendo solo seis gotas de sangre de una punción en el dedo. El sistema puede ser operado por cualquier trabajador de la salud capacitado, sin necesidad de experiencia en flebotomía.
Este desarrollo tiene como objetivo mejorar el acceso a las pruebas de sangre en lugares desatendidos y reducir barreras como el miedo a las agujas y los desafíos logísticos. La asociación, que comenzó en 2016, ya ha implementado las pruebas de sangre BetterWay en entornos minoristas desde mayo de 2024 y ahora se está expandiendo a sitios de atención ambulatoria en los Estados Unidos.
BD (NYSE: BDX)와 Babson Diagnostics가 미국의 건강 시스템 및 제공자 네트워크를 위한 손끝 혈액 샘플 수집 및 검사 기술의 확장을 발표했습니다. 이 혁신은 BD의 MiniDraw™ Capillary Blood Collection System과 Babson의 BetterWay 기술를 결합하여 손가락의 작은 찔림에서 단지 여섯 방울의 혈액만 필요로 합니다. 이 시스템은 채혈 경험이 없는 훈련받은 모든 의료 작업자가 운영할 수 있습니다.
이 개발은 소외된 지역에서 혈액 검사 접근성을 개선하고 바늘에 대한 두려움 및 물류적 문제와 같은 장벽을 줄이는 것을 목표로 하고 있습니다. 2016년에 시작된 이 파트너십은 2024년 5월부터 소매 환경에서 BetterWay 혈액 검사 서비스를 구현했으며, 이제는 미국 전역의 외래 진료 사이트로 확대되고 있습니다.
BD (NYSE: BDX) et Babson Diagnostics ont annoncé une expansion de leurs technologies de collecte et de test de sang par prélèvement au doigt pour les systèmes de santé et les réseaux de fournisseurs aux États-Unis. L'innovation combine le MiniDraw™ Capillary Blood Collection System de BD avec les technologies BetterWay de Babson, nécessitant seulement six gouttes de sang d'une piqûre au doigt. Le système peut être utilisé par tout professionnel de la santé formé, sans expérience en phlébotomie.
Ce développement vise à améliorer l'accès aux tests sanguins dans les zones défavorisées et à réduire des obstacles tels que la peur des aiguilles et les défis logistiques. Le partenariat, qui a commencé en 2016, a déjà mis en œuvre le test sanguin BetterWay dans des environnements de vente au détail depuis mai 2024 et s'étend désormais aux sites de soins ambulatoires à travers les États-Unis.
BD (NYSE: BDX) und Babson Diagnostics haben eine Erweiterung ihrer Technologien zur Blutentnahme und -untersuchung an der Fingerspitze für die Gesundheitssysteme und Anbieter-Netzwerke in den USA angekündigt. Die Innovation kombiniert das MiniDraw™ Capillary Blood Collection System von BD mit Babsons BetterWay-Technologien, die nur sechs Tropfen Blut aus einem Fingerstich benötigen. Das System kann von jedem geschulten Gesundheitsarbeiter ohne Erfahrung in der Phlebotomie bedient werden.
Diese Entwicklung zielt darauf ab, den Zugang zu Blutuntersuchungen in unterversorgten Gebieten zu verbessern und Barrieren wie Angst vor Nadeln und logistische Herausforderungen abzubauen. Die Partnerschaft, die 2016 begann, hat bereits seit Mai 2024 BetterWay-Bluttests in Einzelhandelsumgebungen implementiert und erweitert sich nun auf ambulante Versorgungseinrichtungen in den Vereinigten Staaten.
- Innovation reduces dependency on trained phlebotomists, potentially lowering operational costs
- Expands market reach into underserved locations and new settings like pharmacies
- Strategic partnership since 2016 demonstrates long-term collaboration stability
- None.
Insights
The expansion of BD and Babson's fingertip blood testing technology represents a significant advancement in diagnostic healthcare delivery. The MiniDraw™ Capillary Blood Collection System addresses critical market gaps, particularly the shortage of phlebotomists and access limitations in underserved areas. With
The technology's ability to function with minimal training requirements reduces operational barriers and staffing constraints for healthcare providers. This strategic partnership expansion builds on 8 years of collaboration, suggesting robust technological validation. The successful retail deployment since May 2024 demonstrates market viability and sets a strong foundation for the ambulatory care market penetration.
This partnership expansion positions BD strategically in the growing point-of-care diagnostics market. The technology addresses several key market demands: reduced invasiveness, improved accessibility and operational efficiency. By enabling sample collection by any trained healthcare worker, the solution could significantly reduce operational costs while expanding service capabilities for healthcare providers.
The timing of this expansion, following successful retail implementation, suggests strong market validation and potential for rapid adoption in ambulatory settings. For BD, with its
This innovative blood testing process integrates BD's MiniDraw™ Capillary Blood Collection System with Babson's BetterWay technologies to enable test results from as few as six drops of capillary blood collected from a patient's finger. With this less-invasive alternative to venipuncture blood draws, samples can be collected and prepared by any trained health care worker — including those without prior phlebotomy experience.
With
"In areas of the
The commercial partnership is an expansion of BD and Babson's collaboration to advance capillary blood testing, which started in 2016 and has since evolved into a strategic partnership.
"BetterWay and BD MiniDraw™ are defining what's next in health care," said David Stein, Babson's CEO. "BD has been innovating blood collection technology for 75 years and we believe our partnership will deliver a potentially transformative technology to support innovative and patient-focused health care organizations in better reaching and serving patients."
BetterWay blood testing has been available in retail settings since May 2024, expanding access to blood collection to new locations, including local pharmacies. This continued expansion will bring it to patients in ambulatory care sites throughout
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
About Babson Diagnostics
Babson Diagnostics is a science-driven healthcare technology company that has reimagined blood testing with the launch of its BetterWay blood testing service. BetterWay's patient-friendly, fingertip collection process and ability to be administered without phlebotomists improves population health by increasing adherence to testing. BetterWay for Healthcare Organizations enables health systems and other provider organizations to acquire new patients, increase health equity, and reduce the overall cost of care by deploying BetterWay in a broad range of ambulatory care settings, including physician practices, urgent care clinics, and at community events. The end-to-end BetterWay solution seamlessly integrates BD's MiniDraw capillary collection system with proprietary Babson technologies, including its patented hand warming and sample preparation devices. For more information, visit betterway.com/healthcare-organizations
Forward-Looking Statements
This press release contains certain forward-looking statements regarding the expansion of the use of BD and Babson's fingertip blood collection and testing technologies. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including, without limitation, competitive factors, including the development of new technologies or products by other companies, changes in healthcare practices, the impact of governmental regulation, future market conditions, manufacturing difficulties or delays, or other factors listed in BD's 2024 Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.
Contacts: | |
BD Media Contact: | BD Investor Contact: |
Troy Kirkpatrick | Adam Reiffe |
VP, Public Relations | Sr. Director, Investor Relations |
858.617.2361 | 201.847.6927 |
Babson Diagnostics Media Contact: | |
Joe Foster | |
323-572-5361 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-babson-diagnostics-launch-innovative-fingertip-blood-testing-to-health-care-organizations-302333274.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
How many drops of blood does BD's new MiniDraw testing system require?
When did BDX launch BetterWay blood testing in retail settings?
What are the main advantages of BD's new fingertip blood testing system?
When did BD and Babson Diagnostics begin their partnership?
What healthcare settings will BD's new blood testing system be available in?
